Galanthamine - Pharmacokinetics and pharmacodynamics

Pharmacia

Volumn 51, Issue 1-2, 2004, Pages 23-29

  Tzankova, Virginia ^a   Valchanova, N ^b  

^a MEDICAL UNIVERSITY OF SOFIA   (Bulgaria)

^b Chem Pharmaceut Res Institute   (Bulgaria)

Author keywords

Galanthamine

Indexed keywords

ALKALOID; CHOLINESTERASE INHIBITOR; GALANTAMINE;

ALZHEIMER DISEASE; AMARYLLIDACEAE; CLINICAL PRACTICE; DEGENERATIVE DISEASE; DISEASE COURSE; DRUG ISOLATION; DRUG USE; GALANTHUS; HISTORY OF MEDICINE; HUMAN; LEUCOJUM; MUSCULAR DYSTROPHY; NARCISSUS; NEUROMUSCULAR DISEASE; PHARMACODYNAMICS; PLANT; POLIOMYELITIS; REVIEW; TREATMENT PLANNING;

EID: 12744255245     PISSN: 04280296     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (60)

1. Bulgarian source. 2, 1957, 23.
2. Bulgarian source. 45, 1966, No 4, 27-34.
3. Bulgarian source. 18, 1955, No 4, 21-27.
4. Bulgarian source. 14, 1951, No 6, 27-30.
5. Bulgarian source. 14, 1975, No 3, 171-174.
6. Bulgarian source 1959.
7. Bulgarian source. 12, 1952, 1899-1902.
8. Bulgarian source. 1, 1959, 29-35.
9. Bulgarian source. 15, 1962, 885-889.
10. Bulgarian source. 26, 1963, 72-75.
11. Bulgarian source. 19, 1956, No. 4.
12. Bachus, R. et al. The O-demethylation of the antidementia drug galanthamine is catalised by cytochrome P4502D6. - Pharmacogenetics 1999, 661-668.
13. Barnes, C. A. et al. Chronic treatment of old rats with donepezyl or galanthamine: effects on memory, hyppocampal plasticity and nicotinic receptors. - Neuroscience, 99, 2000, 17-23.
14. Barton, D. H. R. et G. W. Krby. The synthesis of galanthamine. - Proc. Chem. Soc., 1, 1960, 392-393.
15. Bickel, U. et al. Galanthamine: pharmakokinetics, tissue distribution and cholinesterase inhibition in brains of mice. - Neuropharmacol., 30, 1991, 447-454.
16. Bickel, U. et al. Galanthamine: pharmacokinetics, tissue distribution and cholinesterase inhibitionin brain of mice. - Neuropharmacol., 30, 1991, 447-454.
17. Bickel U. et al. Pharmacokinetics of galanthamine in humans and corresponding cholinesterase inhibition. - Clin. Pharmacol. Ther., 50, 1991, 420-428.
18. Bores, G. M. et al. Pharmacological evaluation of novel Alzheimer's disease therapeutics: acetylcholinesterase inhibitors related to galanthamine. - J. Pharmacol. Exp. Ther., 277, 1996, 728-738.
19. Chopin, P. et M. Briley. Effects of non cholinergic cognitive ehhancers in comparison with tacrine and galanthamine on scopolamine - induced amnesia in rats. - Psychopharmacol., 106, 1992, 26-30.
20. Davies, P. et A. J. Maloney. Selective loss of central cholinergic neurons in Alzheimer's disease. - Lancet, 2, 1976, No 8000, 1403.
21. Fishkin, R. J. et al. d-Cycloserine attenuates scopolamine induced learning and memory deficits in rats. - Benav. Neural. Biol., 59, 1993, 150-157.
22. Graves, R. The Greek Myth. Harmondworth, Penguin Books, England, 1960.
23. Greenblatt, H. et al. Structure of acetylcholinesterase complexed with (-) - galanthamine at 2.3 A resolution. - FEBS Lett. 463, 1999, 321-326.
24. Harvey, A. L. The pharmacology of galanthamine and its analogues. - Pharmacol. Ther., 68, 1995, 113-128.
25. Holl, G. et al. Effect of the cholinesterase inhibiting substance galanthamine on human EEG and visual evoked potentials. - Electroencephalogr. Clin. Neurophysiol. 82, 1992, 445-452.
26. Iliev, A. et al. Effect of acetylcholinesterare Inhibitor galanthamine on learning and memory in prolonged alcohol intake rat model of acetylcholine deficit. - Methods Find. Exp. Clin. Pharmacol., 21 1999, No 4, 297-301.
27. Janssen, Reminyt tablets prescribing information, Janssen Pharmaceutica NV, Jul 2000.
28. Jones, R. W. et al. The effect of food on the absorbtion of galanthamine in healty elderly volunteers. - Br. J. Clin. Pharmacol. 42, 1996, 671.
29. Maelicke, A. et E. X. Albuquerque. Allosteric modulation of nicotinic acetylcholine receptors as a treatment strategy for alzhaeimer's disease, - Eur. J. Pharmacol., 393, 2000, 165-170.
30. Maelicke, A. et al. Allosterically potentiating ligands of nicotinic receptors as a treatment strategy for Alzheimer's disease. - Behav. Brain. Res., 213, 2000, 199-206.
31. Maelicke, A. Allosteric modulation of nicotinic receptors as a as a treatment strategy for Alzheimer's disease. - Dement. Geriatr. Cogn. Disord., 11, 2000, Suppl. 1, 11-18.
32. Maelicke, A. et al. Allosteric sensitization of nicotinic receptors by galanthamine, a new treatment strategy for Alzheimer disease. - Biol. Psychiatry, 49, 2001, No 3, 279-88.
33. Mayrhofer, O. Nivalin - Experience with application of galanthamine as an antagonist to the relaxant of curare type. - Bull. Swiss Acad. Med. Sci., 23, 1967, 48-52.
34. Mihailova, D., M. Velkov, et Z. Zhivkova. In vivo metabolism of galanthamine hydrobromide (Nivalin) by rat and rabbit homogenate. - Eur. J. Drug. Metab. Pharmacokinet., 12, 1987, 25-30.
35. Mihailova, D. et al. Pharmacokinetics of galanthamine after single subcutaneous and oral dosage in humans. - Pharmacology, 39, 1989, 50-58.
36. Nastev, G. Nivalin treatment of patients with diseases of nervous system. - Cultura medica. (Roma), 15, 1960, 87-97.
37. Paskov, D. S. et al. Clinical experience with Nivaline as anticholinesterase drug in anaestiological practice. - Proc. First. Eur. Congr. Anaesthesiol., Vienna, 3-9 Sept, 1962.
38. Plaitakis, A. et R. C. Duvoisin. Homer's moly identified as Galanthus nivalis L.: physiologic antidote to stramonium poisoning. - Clin. Neuropharmacol., 6, 1983, No 1, 1-5.
39. Proscurina, N. F. et A. P. Yakovleva. Alkaloids of Gallantus woronovi II. Isolation of a new alkaloid (abs). - Chem. Abs., 47, 1953, 6959.
40. Poulev, A., B. Deus-Neumann et M. H. Zenk. Enzyme immunoassay for the quantitative determination of galanthamine. - Planta Med., 59 1993, 442-446.
41. Pereira, E. F. et al. Identification and functional characterization of new agonist site on nicotinic acetylcholine receptors of cultured hippocampal neurons. - J. Pharmacol. Exp. Ther., 265, 1993, 603-605.
42. Pereira, E. F. et al. Physostigmine and galanthamine: probes for a novel binding site on alfa 4 beta 2 subtype of neuronal nicotinic acetylcholine receptors stably expressed in fibroblast cells. - J. Pharmacol. Exp. Ther., 270, 1994, 768-778.
43. Raskind, M. A. et al. Galanthamine in AD: a 6- month randomised placebo-controlled trial with a 6 month extension. - Neurology, 54, 2000, 2261-2268.
44. Stoyanov, E. A. Galanthaminum hydrobromicum "Nivalin" ein neues Antidot der nichtdepolarisierenden Muskelrelaxantien. - Pharmakologie und klinische Anwendung. Der. Anaesthesist., 13, 1964, No 7, 217-220.
45. Strobbia, R., R. Lalloni et U. Dalzotto. The association of Nivalin with vitamins of the B group (B1, B6, B12) and pyridoxal phosphate in the therapy of neuritis and neuralgia. - Minerva Med., 59 1968, No 86, 4566-4577.
46. Schrattenholtz, A. et al. Photoaffinity labelling of Torpedo acetylcholine receptors by physostigmine. - Eur. J. Biochem., 216, 1993, 671-677.
47. Sweeney, J. E., E. S. Bachman et J. T. Coyle. Effects of different doses galanthamine, a long acting acetylcholinesterase inhibitor on memory in mice. - Psychopharmacol. Bull., 102, 1990, 191-200.
48. Sweeney, J. E., P. S. Puttfareken et J. T. Coyle. Galanthamine, an acetylcholinesterase inhibitor: a time course of the effects on performance and neurochemical parameters in mice. - Pharmacol. Biochem. Behav., 34, 1989, 129-138.
49. Storch, A. et al. Physostigmine, galanthamine and codeine act as non-competitive nicotinic receptor agonists on clonal rat pheochromocytoma cells. - Eur. J. Pharmacol., 290, 1995, 207-219.
50. Schroder, B. et al. Monoclonal antibodies FK1 and WF6 define two neighbouring ligand binding sites on Torpedo acetylcholine receptor alfa-polypeptide. - J. Biol. Chem., 269, 1994, 1047-1016.
51. Schrattenholz, A. et al. Agonist responces of neuronal nicotinic acetylcholine receptors are potentiated by a novel class of allosterically acting ligands. - Mol. Pharmacol., 106, 1996, 26-30.
52. Sweeney, J. E. et al. Along acting cholinesterase inhibitor reverses spatial memory deficits in mice. - Pharmacol. Biochem. Behav., 31, 1988, 141-147.
53. Tariot, P. N. et al. A 5-month randomised placebo-controlled trial of galanthamine in AD. - Neurology, 54, 2000, 2269-2276.
54. Thomsen, T. et al. Inhibition of acetylcholinesterase activity in human brain tissue and erytrocytes by galanthamine, physostigmine and tacrine. - Eur. J. Clin. Chem. Clin. Biochem., 29 1991, 487-492.
55. Thomsen, T. et al. Stereoselectivity of cholinesterase inhibition by galanthamine and tolerance in humans. - Eur. J. Clin. Pharmacol., 39, 1990, 603-605.
56. Thomsen, T. et H. Kewitz. Selective inhibition of human acetylcholinesterase by galanthamine in vitro and in vivo. - Life Sci., 46, 1990, 1553-1558.
57. Thomsen, T. et al. In vivo effects of various cholinesterase inhibitors on acetyl - and butyryl - cholinesterase of healthy volunteers. - Biochem. Pharmacol., 41, 1991, No 1, 139-141.
58. Venkov, L., M. Eskenazy, et S. Mladenov. Effect of nivalin on the activity of ali-esterases, acetyl and butyrylcholinesterase of rabbit spinal cord. - Comptes rendus de l'Academie bulgare des sciences, 20 1967, No 8, 863-865.
59. Woodruff-Pak, D. S., R. W. Vogel, et G. L. Wenk. Galanthamine: effect on nicotinic binding, anticholinesterase inhibition and learning. - Proc. Natl. Acad. Sci. USA, 98, 2001, No 4, 2089-2094.
60. Wood, D. M. et al. Plasma protein binding of galanthamine: a potential agent for the treatment of Alzheimer's disease. - Eur. J. Clin. Pharmacol., 23, 1997, Suppl. A, 161.